KAT-101 / NewG Lab Pharma - LARVOL DELTA

KAT-101 in Subjects With Hepatocellular Carcinoma (HCC) (clinicaltrials.gov) - P1/2 | N=148 | Suspended | Sponsor: Primocure Pharma | Trial completion date: Nov 2025 ➔ Nov 2027 | Active, not recruiting ➔ Suspended | Trial primary completion date: Nov 2025 ➔ Nov 2027

Trial completion date • Trial primary completion date • Trial suspension • Hepatocellular Cancer • Oncology • Solid Tumor

KAT-101 in Subjects With Hepatocellular Carcinoma (HCC) (clinicaltrials.gov) - P1/2 | N=148 | Active, not recruiting | Sponsor: Primocure Pharma

Trial completion date • Trial primary completion date • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor

KAT-101 in Subjects With Hepatocellular Carcinoma (HCC) (clinicaltrials.gov) - P1/2 | N=148 | Active, not recruiting | Sponsor: NewG Lab Pharma | Recruiting ➔ Active, not recruiting

Enrollment closed • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor

KAT-101 in Subjects With Hepatocellular Carcinoma (HCC) (clinicaltrials.gov) - P1/2 | N=148 | Recruiting | Sponsor: NewG Lab Pharma

New P1/2 trial • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor